The data presented here demonstrates that depleting USP17 can not only block the proliferation of NSCLC cells which are EGFRWT, but also NSCLC cells bearing activating mutations of EGFR, as well as those with secondary gatekeeper EGFR mutations. Here, USP17L2 is linked to non-small cell lung carcinoma.